By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine said Wednesday that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG's common stock for $7 per share.

In total, BG sold 5.75 million shares at a price of $7 per share in the offering. The firm said in its prospectus for the offering that if the underwriters' over-allotment option was exercised in full, its net proceeds would be approximately $35.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.